Medicare AdvantageCoverageMedium impact
MA08.070f, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology·Pharmacy
Effective date
Aug 6, 2025
We identified it
Jun 19, 2026
Summary
The Medicare Advantage policy for Golimumab (Simponi Aria®) IV injection has been reissued and will take effect on August 6, 2025. This is an updated pharmacy policy that may contain changes to coverage criteria, prior authorization requirements, or administration guidelines for this biologic medication used primarily for autoimmune conditions.
Action Required
By August 6, 2025: Billing team must review the complete updated policy MA08.070f for Golimumab (Simponi Aria®) IV injection at the source URL to identify specific changes to prior authorization requirements, coverage criteria, or billing procedures. Update billing system and staff training accordingly for Medicare Advantage patients receiving this treatment.